Stryker Corp
$115.42B- Market cap
- $103.57B
- Debt
- +$15.86B
- Cash
- −$4.01B
Capital structure 87% equity / 13% debt · EV / Revenue 4.60x · EV proxy / EBITDA proxy 17.87x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $103.57B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
FY 2025 ·
Decision snapshot: SYK stock price near parity vs ZBH $270.01 current versus $218.73 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ZBH's multiple
Implied fair value · at SYK's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 87% equity / 13% debt · EV / Revenue 4.60x · EV proxy / EBITDA proxy 17.87x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
STRYKER CORP · implied price per share
Bear
$103.67
Base
$129.90
Bull
$165.28
ZIMMER BIOMET HOLDINGS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
SYK vs ABT
JOHNSON & JOHNSON
SYK vs JNJ
BAXTER INTERNATIONAL INC
SYK vs BAX
INTUITIVE SURGICAL INC
SYK vs ISRG
ALIGN TECHNOLOGY INC
SYK vs ALGN
ARTIVION, INC.
SYK vs AORT
Medtronic plc
SYK vs MDT
Orthofix Medical Inc.
SYK vs OFIX
SMITH & NEPHEW PLC
SYK vs SNN
CONMED Corp
SYK vs CNMD
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe SYK can sustain its superior margin structure and growth while justifying a persistent premium multiple, then hold or accumulate on weakness because its fundamentals are clearly stronger than ZBH’s; otherwise, the current price looks stretched versus the implied P/E value and historical range.
SYK trades at a premium to ZBH on every major valuation metric provided, including P/E, P/S, EV/EBITDA, and EV/Revenue. Despite stronger fundamentals, the implied P/E price of $228.46 is 32.6% below the current price of $339.03, suggesting the market is embedding a sizable quality premium.
Supporting Metrics